Home Cart Sign in  
Chemical Structure| 17086-76-9 Chemical Structure| 17086-76-9

Structure of Cyasterone
CAS No.: 17086-76-9

Chemical Structure| 17086-76-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Cyasterone is an inhibitor of EGFR that maybe a promising anti-cancer agent espcially in skin carcinoma.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Cyasterone

CAS No. :17086-76-9
Formula : C29H44O9
M.W : 536.65
SMILES Code : O=C1[C@@H](C)[C@H](C[C@@H](O)[C@@]([C@H]2CCC3(O)C4=CC([C@]5([H])C[C@@H](O)[C@@H](O)C[C@]5(C)[C@@]4([H])CC[C@]23C)=O)(O)C)[C@@H](O)CO1
MDL No. :MFCD01683622

Safety of Cyasterone

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Cyasterone

RTK
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • EGFR/ErbB1

In Vitro:

Cell Line
Concentration Treated Time Description References
MLE-12 cells 10 μM, 30 μM, 100 μM 24 h Cyasterone reduced cellular and mitochondrial ROS levels and effectively inhibited LPS-induced cell apoptosis. Chin Med. 2023 Oct 19;18(1):136
Primary murine peritoneal macrophages 10 μM, 30 μM, 100 μM 24 h Cyasterone pretreatment significantly reduced LPS-induced inflammatory factor expression, including IL-6, IL-1β, TNF-α, and COX-2, and inhibited NLRP3 inflammasome activation. Chin Med. 2023 Oct 19;18(1):136
Human umbilical vein endothelial cells (HUVECs) 50, 100, 200 μM 24 h To evaluate the protective effects of Cyasterone on thrombin-induced HUVECs injury model. Results showed that Cyasterone significantly inhibited the levels of TXA2, ET, MDA, and COX-2 and promoted the activities of eNOS and SOD. Pharmacogn Mag. 2017 Oct-Dec;13(52):693-701
Rat bone marrow mesenchymal stem cells (MSCs) 10 μg/ml 14 days To evaluate the effect of Cyasterone on MSCs osteogenic differentiation, results showed that Cyasterone significantly promoted MSCs osteogenic differentiation. J Orthop Translat. 2021 Feb 19;28:28-38
Rat bone marrow mesenchymal stem cells (MSCs) 5 and 10 μg/ml 12 h To evaluate the effect of Cyasterone on MSCs migration capacity, results showed that Cyasterone significantly promoted MSCs migration. J Orthop Translat. 2021 Feb 19;28:28-38
Rat bone marrow mesenchymal stem cells (MSCs) 2.5, 5, 10, 20, 40, 80 μg/ml 24~48 h To evaluate the effect of Cyasterone on MSCs proliferation, results showed that Cyasterone significantly promoted MSCs proliferation at concentrations of 2.5–10μg/ml. J Orthop Translat. 2021 Feb 19;28:28-38

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Cecal ligation and puncture (CLP)-induced sepsis-related acute lung injury model Intraperitoneal injection 1 mg/kg/d, 5 mg/kg/d, 25 mg/kg/d Once daily for 3 days Cyasterone pretreatment attenuated CLP-induced lung histopathological damage and oxidative stress, reduced inflammatory factor secretion, and inhibited NLRP3 inflammasome activation. Chin Med. 2023 Oct 19;18(1):136

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.86mL

0.37mL

0.19mL

9.32mL

1.86mL

0.93mL

18.63mL

3.73mL

1.86mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories